A customer in (b)(6) reported (b)(6) results in association with the chromid tm mrsa agar ( (b)(4), lot 1004074290, expiry 27aug15).The customer indicated the bacteria growth appeared green (resistant) on the chromid mrsa agar.However, the strain was confirmed to be (b)(6) (susceptible) using a (b)(6) screening test, vitek 2 and cefoxitin disc diffusion.The customer claims minimal delay (<24 hours) for the confirmation test results, and that the discrepant chromid mrsa result was not reported to the physician.Customer qc for the incriminated lot provided results in accordance with specification.Sop 029481, 4.2.4 § erroneous ast, states that a(b)(6) result is considered as serious because inappropriate treatment could be provided leading to treatment failure.(b)(4), § principle, states there is detection of mrsa strains by revealing green colonies.It should be noted that within the ifu, in the summary and explanation paragraph , there is a cautionary note stating this medium does not replace conventional antimicrobial susceptibility tests.There is no indication or report from the hospital or treating physician to biomedieux that the discrepant chromid mrsa result led to any adverse event related to the patient's state of health.Strain submittals have been requested from the customer.Biomedieux internal investigation has been initiated.
|